Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2022 07:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor,...
April 26, 2022 07:30 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology

KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319,...
May 18, 2020 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

KNOXVILLE, TN, May 18, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from ongoing preclinical study of investigational...
February 19, 2019 07:30 ET | Source: Provectus Biopharmaceuticals Inc.

Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy

Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...